Floatz logo

TACROLIMUS

Moderate/Severe Atopic Dermatitis

Astellas Pharma China, Inc.Small moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Moderate/Severe Atopic Dermatitis cohort.

Asset / SponsorPhaseRating
pf-04965842
Pfizer
Phase 2CCC
Broncho-Vaxom
OM Pharma SA
Phase 2CCC
Dupilumab
Sanofi
Phase 2CCC
Itepekimab
Regeneron Pharmaceuticals
Phase 2CC

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →